One year after achieving landmark approval in China for the first ever China-discovered and developed targeted oncology drug to receive unconditional approval (fruquintinib, for colorectal cancer), the Hong Kong-headquartered and Nasdaq-listed Chi-Med is on the way to commercializing its second China-developed drug, this time for advanced non-pancreatic neuroendocrine tumors (NETs).
China’s National Medical Products Administration (NMPA) has accepted Hutchison China MediTech’s (Nasdaq: HCM), also known as Chi-Med, New Drug Application (NDA) for surufatinib to treat non-pancreatic NETs, reflecting the accelerated pace of drugs approvals in China and Chi-Med’s commitment to advance its pipeline of novel therapies in China and globally. Chi-Med’s shares closed up 3.5% at 360 pence today
Unlike Chi-Med’s first approved drug, Elunate (fruquintinib), which is marketed by Eli Lilly (NYSE: LLY) in China, the company plans to commercialize surufatinib using its own commercial organization, which covers over 24,400 hospitals in over 330 cities and towns in China. Both drugs are undergoing proof of concept trials in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze